A few studies have assessed vaccine candidates eliciting CD8 + and/or CD4 + T cells that correlate with protection from liver-stage infection in mice [40, 41] and one clinical trial [42], but the mechanism that leads to T cell protection remains to be elucidated. This evidence concerns the gene CD4 and infection.